EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Oberoi, Pranav ^a   Jabulowsky, Robert A ^a   Bähr Mahmud, Hayat ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANZYME B; GRANZYME B TRANSFORMING GROWTH FACTOR BETA FUSION PROTEIN; HYBRID PROTEIN; IONOMYCIN; LENTIVIRUS VECTOR; MESSENGER RNA; PERFORIN; POLYMETHACRYLIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DEGRANULATION; DNA MODIFICATION; ENZYME RELEASE; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR CELL DESTRUCTION;

APOPTOSIS; CELL DEGRANULATION; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GRANZYMES; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; KILLER CELLS, NATURAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84875721355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061267     Document Type: Article

References (45)

1. Smyth MJ, Hayakawa Y, Takeda K, Yagita H, (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850-861.
2. Lanier LL, (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495-502.
3. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, et al. (2001) The immunological synapse. Annu Rev Immunol 19: 375-396.
4. Huse M, Quann EJ, Davis MM, (2008) Shouts, whispers and the kiss of death: directional secretion in T cells. Nat Immunol 9: 1105-1111.
5. Cullen SP, Brunet M, Martin SJ, (2010) Granzymes in cancer and immunity. Cell Death Differ 17: 616-623.
6. Chowdhury D, Lieberman J, (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26: 389-420.
7. Pham CT, Ley TJ, (1999) Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc Natl Acad Sci U S A 96: 8627-8632.
8. Afonina IS, Cullen SP, Martin SJ, (2010) Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 235: 105-116.
9. Rosenblum MG, Barth S, (2009) Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 15: 2676-2692.
10. Kurschus FC, Jenne DE, (2010) Delivery and therapeutic potential of human granzyme B. Immunol Rev 235: 159-171.
11. von Minckwitz G, Harder S, Hövelmann S, Jäger E, Al-Batran SE, et al. (2005) Phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 7: R617-R626.
12. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG, (2003) Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2: 1341-1350.
13. Kurschus FC, Kleinschmidt M, Fellows E, Dornmair K, Rudolph R, et al. (2004) Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 562: 87-92.
14. Giesübel U, Dälken B, Mahmud H, Wels WS, (2006) Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeast Pichia pastoris. Biochem J 394: 563-573.
15. Dälken B, Giesübel U, Knauer SK, Wels WS, (2006) Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition. Cell Death Differ 13: 576-585.
16. Dälken B, Jabulowsky RA, Oberoi P, Benhar I, Wels WS, (2010) Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein. PLoS One 5: e14404.
17. Gehrmann M, Doss BT, Wagner M, Zettlitz KA, Kontermann RE, et al. (2011) A novel expression and purification system for the production of enzymatic and biologically active human granzyme B. J Immunol Methods 371: 8-17.
18. Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, et al. (2006) Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity. Neoplasia 8: 125-135.
19. Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, et al. (2008) Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7: 2924-2932.
20. Jabulowsky RA, Oberoi P, Bähr-Mahmud H, Dälken B, Wels WS, (2012) Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFalpha fusion protein. Bioconjug Chem 23: 1567-1576.
21. Hynes NE, MacDonald G, (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
22. Mendelsohn J, Baselga J, (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
23. Groner B, Hartmann C, Wels W, (2004) Therapeutic antibodies. Curr Mol Med 4: 539-547.
24. Wels W, Biburger M, Müller T, Dälken B, Giesübel U, et al. (2004) Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol Immunother 53: 217-226.
25. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, et al. (1987) Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 252: 549-560.
26. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L, (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494.
27. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, et al. (2002) Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273.
28. Imai C, Iwamoto S, Campana D, (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383.
29. Müller T, Uherek C, Maki G, Chow KU, Schimpf A, et al. (2008) Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57: 411-423.
30. Pegram HJ, Jackson JT, Smyth MJ, Kershaw MH, Darcy PK, (2008) Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 181: 3449-3455.
31. Sahm C, Schönfeld K, Wels WS, (2012) Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother 61: 1451-1461.
32. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, et al. (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24: 406-415.
33. Kurschus FC, Fellows E, Stegmann E, Jenne DE, (2008) Granzyme B delivery via perforin is restricted by size, but not by heparan sulfate-dependent endocytosis. Proc Natl Acad Sci U S A 105: 13799-13804.
34. Henkart PA, Millard PJ, Reynolds CW, Henkart MP, (1984) Cytolytic activity of purified cytoplasmic granules from cytotoxic rat large granular lymphocyte tumors. J Exp Med 160: 75-93.
35. Ishiura S, Matsuda K, Koizumi H, Tsukahara T, Arahata K, et al. (1990) Calcium is essential for both the membrane binding and lytic activity of pore-forming protein (perforin) from cytotoxic T-lymphocyte. Mol Immunol 27: 803-807.
36. Voskoboinik I, Thia MC, Fletcher J, Ciccone A, Browne K, et al. (2005) Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491. J Biol Chem 280: 8426-8434.
37. Chatila T, Silverman L, Miller R, Geha R, (1989) Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 143: 1283-1289.
38. Morgan AJ, Jacob R, (1994) Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane. Biochem J 300: 665-672.
39. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, et al. (1996) New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 271: 29073-29079.
40. Trapani JA, Smyth MJ, (2002) Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2: 735-747.
41. Stewart SE, D'Angelo ME, Bird PI, (2012) Intercellular communication via the endo-lysosomal system: translocation of granzymes through membrane barriers. Biochim Biophys Acta 1824: 59-67.
42. Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, et al. (1990) Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci U S A 87: 3655-3659.
43. Mahmud H, Dälken B, Wels WS, (2009) Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther 8: 1526-1535.
44. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803-813.
45. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D, (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875.